BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 30379750)

  • 1. Investigating the histopathologic correlates of 18F-FDG PET heterogeneity in non-small-cell lung cancer.
    Bashir U; Foot O; Wise O; Siddique MM; Mclean E; Bille A; Goh V; Cook GJ
    Nucl Med Commun; 2018 Dec; 39(12):1197-1206. PubMed ID: 30379750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intra-tumour 18F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging.
    Dong X; Wu P; Sun X; Li W; Wan H; Yu J; Xing L
    J Med Imaging Radiat Oncol; 2015 Jun; 59(3):338-45. PubMed ID: 25708154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies.
    van Velden FH; Cheebsumon P; Yaqub M; Smit EF; Hoekstra OS; Lammertsma AA; Boellaard R
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1636-47. PubMed ID: 21617975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Texture Analysis on [
    Bianconi F; Palumbo I; Fravolini ML; Chiari R; Minestrini M; Brunese L; Palumbo B
    Mol Imaging Biol; 2019 Dec; 21(6):1200-1209. PubMed ID: 30847822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
    Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
    J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer.
    Tixier F; Vriens D; Cheze-Le Rest C; Hatt M; Disselhorst JA; Oyen WJ; de Geus-Oei LF; Visser EP; Visvikis D
    J Nucl Med; 2016 Jul; 57(7):1033-9. PubMed ID: 26966161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different (18)F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?
    Groheux D; Majdoub M; Tixier F; Le Rest CC; Martineau A; Merlet P; Espié M; de Roquancourt A; Hindié E; Hatt M; Visvikis D
    Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1682-1691. PubMed ID: 26140849
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Jreige M; Letovanec I; Chaba K; Renaud S; Rusakiewicz S; Cristina V; Peters S; Krueger T; de Leval L; Kandalaft LE; Nicod-Lalonde M; Romero P; Prior JO; Coukos G; Schaefer N
    Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1859-1868. PubMed ID: 31214790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeatability of Quantitative Whole-Body 18F-FDG PET/CT Uptake Measures as Function of Uptake Interval and Lesion Selection in Non-Small Cell Lung Cancer Patients.
    Kramer GM; Frings V; Hoetjes N; Hoekstra OS; Smit EF; de Langen AJ; Boellaard R
    J Nucl Med; 2016 Sep; 57(9):1343-9. PubMed ID: 27103020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation study on 18F-FDG PET/CT metabolic characteristics of primary lesion with clinical stage in lung cancer.
    Hu WD; Wang HC; Wang YB; Cui LL; Chen XH
    Q J Nucl Med Mol Imaging; 2021 Jun; 65(2):172-177. PubMed ID: 30916535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pilot Study of Texture Analysis of Primary Tumor [
    Nakajo M; Jinguji M; Shinaji T; Aoki M; Tani A; Nakabeppu Y; Nakajo M; Sato M; Yoshiura T
    Mol Imaging Biol; 2019 Aug; 21(4):771-780. PubMed ID: 30397859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
    Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
    Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consistency of metabolic tumor volume of non-small-cell lung cancer primary tumor measured using 18F-FDG PET/CT at two different tracer uptake times.
    Liu H; Chen P; Wroblewski K; Hou P; Zhang CP; Jiang Y; Pu Y
    Nucl Med Commun; 2016 Jan; 37(1):50-6. PubMed ID: 26426969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
    Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variability and Repeatability of Quantitative Uptake Metrics in
    Zhuang M; García DV; Kramer GM; Frings V; Smit EF; Dierckx R; Hoekstra OS; Boellaard R
    J Nucl Med; 2019 May; 60(5):600-607. PubMed ID: 30389824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of texture analysis of dual-time-point
    Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
    Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT.
    Sauter AW; Winterstein S; Spira D; Hetzel J; Schulze M; Mueller M; Pfannenberg C; Claussen CD; Klotz E; Hann von Weyhern C; Horger MS
    J Nucl Med; 2012 Apr; 53(4):521-9. PubMed ID: 22414637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.